Chairman and Co-Founder: Rob Ryan

Founder and former CEO, Ascend Communications, Inc.

Founding Chairman, Silicon Spice

Principal, Entrepreneur America

 

Rob Ryan, founder of Ascend Communications and Entrepreneur America, was honored as Cornell Entrepreneur of the Year in 2002. Ryan earned national attention when he grew his 1989 start-up company, Ascend, to more than $500 million in sales by 1995. Lucent Technologies acquired Ascend in 1999 for $23 billion, in what was termed the "largest technology merger ever."

 

Partner Emeritus, Kleiner, Perkins, Caufield & Byers

 

Jim Lally began his career in technology as a practicing engineer in advanced thin film research at TRW. Later, at H-P, he was responsible for H-P's minicomputer product line, and was a highly-regarded salesperson before joining Intel. At Intel he founded three major microcomputer systems divisions, serving as the GM, with P&L responsibility for each.

 

Founder and CEO, MagiQ Technologies, Inc.

Former Managing Director, Millennium Partners

 

Mr. Gelfond is the CEO of MagiQ, whose mission is to perform R&D on the exploitation of quantum information technology. He is an active angel investor who was, for instance, a first-round investor in Amazon.com.  Prior to MagiQ, Mr. Gelfond developed quantitative financial forecasting and risk models and profitably managed a portfolio of currencies, equities, and fixed income instruments.  Prior to that, he was Director of International Trading at D. E. Shaw & Co.

 

Managing Director and CEO, Navigator Technology Ventures

Co-founder, Viewlogic Systems, Inc.

Co-founder, CommonAngels

 

Mr. Hanover has over 30 years of experience in venture capital, executive management, software development, and engineering. In 1984 he co-founded and served as President, CEO, and Chairman of Viewlogic Systems, an EDA company, which he took public in 1991 and grew to $150M in sales when it was sold to Synopsys in 1997.  He was award the Entrepreneur of the Year Award in 1993.  More recently, Mr. Hanover co-founded CommonAngels, Boston's leading angel investor group.

 

Gregg Favalora - Actuality President & CEO, CTO

Medical Advisory Board

 

Bradley R. Prestidge, MD (Chairman, Actuality Brachytherapy Advisory Board)

Chief Medical Officer, Texas Cancer Clinic

 

Dr. Prestidge is the founder, President, CEO, and Medical Director of the Texas Cancer Clinic and Texas Prostate Clinic - the largest prostate seed implant program in Texas and the remaining South Central United States. Dr. Prestidge is an international expert and was the consultant to the Surgeon General for five years. The author of more than 50 peer-reviewed journal articles, he sits on editorial boards of several journals, is an educator for prostate brachytherapy at ASTRO and RSNA, and teaches courses in advanced prostate seed implantation. He trained at Stanford University and is board certified in Radiation Oncology.

 

Chief of Medical Physics, Texas Cancer Clinic

 

Dr. Sadeghi is the Chief of Medical Physics at the Texas Cancer Clinic. Dr. Sadeghi oversees the physicists, medical dosimetrists, and graduate students. He is in charge of the radiation treatment planning for MammoSite patients. He is also an assistant professor of the radiological sciences division of the Department of Radiology at the University of Texas Health Science Center (San Antonio). His professional experience includes over 12 years of research, training, consulting, and treatment planning in radiological physics. Dr. Sadeghi received a bachelor's degree from Louisiana State University in 1984 and a masters of science in medical physics from the University of Texas Health Science Center at San Antonio in 1994 where he also completed his Ph.D. in radiological sciences in 1996. He has 27 technical papers covering prostate dosimetry, dose evaluation, and positioning accuracy.

 

Chief of Radiation Physics, Rush Memorial Hospital

 

Dr. Chu is Consulting Director of Radiation Oncology Physics for Actuality. He serves as a professor in radiation oncology and medical physics at Rush Medical College (Chicago). Prior to this position, Dr. Chu held various radiation physics professorial and faculty positions at the University of Pennsylvania School of Medicine, the Health Physics Society, and the University of Texas (Arlington), working for the department of physics. Dr. Chu's many accomplishments have been recognized with numerous awards and honors, such as being listed in the "Who's Who in Science and Engineering" (1993-2001) as well as acknowledgment in 2000 in a list of "Outstanding Scientists in the 20th Century."  He has 38 technical papers covering dosimetry, treatment planning, information display, and clinical effects of radiation.

 

Michael J. Zelefsky, MD

 

 

Dr. Zelefsky's work has shown that higher cure rates can be achieved with the safe delivery of unprecedented high doses of radiation. In collaboration with colleagues from the Center's Medical Physics Department, he is implementing sophisticated and innovative techniques in brachytherapy for prostate cancer, breast cancer, soft-tissue sarcoma, and head-and-neck malignancies.  Dr. Zelefsky earned his MD degree at Albert Einstein College of Medicine and did his residency in Radiation Oncology at Memorial Sloan-Kettering Cancer Center. He is board certified in radiation oncology.

 

Asst. Prof. of Radiation Oncology, Beth Israel Deaconess Medical Center

 

Dr. Kaplan's focus and research on prostate cancer spans more than 20 years. His research and publications have centered on techniques and technologies to improve morbidity, accuracy, and quality of brachytherapy. Dr. Kaplan has four U.S. patents and 33 peer-reviewed papers, with eight specifically on prostate brachytherapy, concentrating on intraoperative treatment planning, seed finding and localization error, and CT / MR image guidance. He earned his MD from Stanford University, where he also did his residency. He is board certified in radiation oncology.

 

Director of Medical Physics, Beth Israel Deaconess Medical Center

 

Dr. Holupka is considered one of the most inventive physicists in radiation oncology. As one of the early technologists in radiation planning software, he developed novel radiation treatment technologies, including treatment planning, image fusion, and treatment protocols that are now used by leading medical software companies. He has four patents related to image guidance and virtual reality for surgical procedures and 15 papers covering seed finding, real-time dosimetry, and seed placement precision. He received his Ph.D. in Physics from Brown University.

 

Professor and Clinical Director, Radiation Oncology, Washington University School of Medicine / Siteman Cancer Center (St. Louis, MO).

 

Dr. Michalski specializes in genitourinary and pediatric oncology and conducts clinical research on the use of radiation therapy for treatment of prostate and other cancers. He is well-published in prostate cancer, as well as image-guided therapy, conformal therapy, and alternate prostate treatment. He earned his MD from the Medical College of Wisconsin and did his residency at Columbia-Presbyterian Medical Center and the Mallinckrodt Institute of Radiology-Washington University School of Medicine. He is board certified in Radiation Oncology.

 

Joseph Bonventre, MD, Ph.D., holds appointments as the Robert H. Ebert Professor of Medicine at Harvard Medical School and Professor of Health Sciences and Technology at MIT. He is Director of the Renal Division of the Brigham and Women's Hospital. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians, and the American Institute for Medical and Biological Engineering. Dr. Bonventre is a member of the Council of the American Society of Nephrology and future president of that organization. He Chairs the Kidney Group of the Harvard Stem Cell Initiative and is co-chair of the Stem Cell, Regenerative Medicine and Tissue Engineering Center of the Brigham and Women's Hospital Research Institute and co-chair of the Technology in Medicine initiative at the Brigham.

 

Dr. Bonventre is a member of the Board of Directors of the National Space Biology Research Institute and the Board of Advisors of the Norwegian Institute for Science and Technology. He is a cofounder of Patientkeeper, Inc. and Pacific Biosciences, Inc. and has been a member of the Scientific Advisory Board of a number of biotechnology companies.

 

In addition to his BS with distinction in Engineering Physics from Cornell, Dr. Bonventre holds M.D. and Ph.D. degrees in biophysics from Harvard University. He has honorary doctorate degrees from Mt. Saint Mary's College and from the Norwegian Institute of Science and Technology in Norway.